How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Interventional procedure overview of ab interno canaloplasty for open-angle glaucoma

    Closed for comments This consultation ended on at   Request commenting lead permission

    Additional information considered by IPAC

    Professional experts' opinions

    Expert advice was sought from consultants who have been nominated or ratified by their professional Society or Royal College. The advice received is their individual opinion and is not intended to represent the view of the society. The advice provided by professional experts, in the form of the completed questionnaires, is normally published in full on the NICE website during public consultation, except in circumstances but not limited to, where comments are considered voluminous, or publication would be unlawful or inappropriate.

    Four professional expert questionnaires for ab interno canaloplasty for open-angle glaucoma were submitted and can be found on the NICE website.

    Patient commentators' opinions

    NICE's Public Involvement Programme sent questionnaires to NHS trusts for distribution to patients who had the procedure (or their carers). NICE received 3 completed questionnaires.

    Company engagement

    A structured information request was sent to 2 companies who manufacture a potentially relevant device for use in this procedure. NICE received 2 completed submissions. These were considered by the IP team and any relevant points have been taken into consideration when preparing this overview.

    Issues for consideration by IPAC

    • Most studies using the OMNI device were included in Appendix A. This is because the OMNI device is capable of ab interno canaloplasty and trabeculotomy and these studies used both techniques. This overview is focused on ab interno canaloplasty alone.

    • A randomised controlled trial of OMNI vs. iTrack for open-angle glaucoma is upcoming (NCT04769453). This is sponsored by Nova Eye, the manufacturer of the iTrack device.